Literature DB >> 16941573

Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.

Karen Le Moguen1, Hubert Lincet, Edwige Deslandes, Marie Hubert-Roux, Catherine Lange, Laurent Poulain, Pascal Gauduchon, Bruno Baudin.   

Abstract

Ovarian cancer is one of the leading causes of mortality due to gynaecological cancer. Despite a good response to surgery and initial chemotherapy essentially based on cisplatin (cis-diamino-dichloro-platinum(II) (CDDP)) compounds, late tumour detection and frequent recurrences with chemoresistance acquisition are responsible for poor prognosis. Several mechanisms have been implicated in CDDP resistance but they are not sufficient to exhaustively explain this resistance emergence. We applied a proteomic approach based on 2-DE coupled with MS to identify proteins associated with the chemoresistance process. We first established a proteomic pattern of the CDDP sensitive ovarian cell line IGROV1 using MALDI-TOF-MS and PMF. We then compared this 2-D pattern with that of the CDDP-resistant counterpart IGROV1-R10. Among the 40 proteins identified, cytokeratins 8 and 18 and aldehyde dehydrogenase 1 were overexpressed in IGROV1-R10, whereas annexin IV was down-regulated. These observations have been confirmed by Western blotting. The characterization of such variations could lead to the development of new protein markers or to the establishment of new therapeutic strategies. Moreover, the identification of proteins involved in CDDP resistance in ovarian tumours would be useful in completing our understanding on this complex mechanism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16941573     DOI: 10.1002/pmic.200500925

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  11 in total

Review 1.  Proteomics and ovarian cancer: integrating proteomics information into clinical care.

Authors:  John L Hays; Geoffrey Kim; Iulia Giuroiu; Elise C Kohn
Journal:  J Proteomics       Date:  2010-06-01       Impact factor: 4.044

2.  Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method.

Authors:  Fengming Gong; Xingchen Peng; Zhi Zeng; Ming Yu; Yuwei Zhao; Aiping Tong
Journal:  Mol Cell Biochem       Date:  2010-11-16       Impact factor: 3.396

3.  Proteomics Analysis of Ovarian Cancer Cell Lines and Tissues Reveals Drug Resistance-associated Proteins.

Authors:  Isa N Cruz; Helen M Coley; Holger B Kramer; Thumuluru Kavitah Madhuri; Nur A M Safuwan; Ana Rita Angelino; Min Yang
Journal:  Cancer Genomics Proteomics       Date:  2017-01-02       Impact factor: 4.069

4.  Proteomic analysis of NME1/NDPK A null mouse liver: evidence for a post-translational regulation of annexin IV and EF-1Bα.

Authors:  Arnaud Bruneel; Dominique Wendum; Valérie Labas; Odile Mulner-Lorillon; Joelle Vinh; Nelly Bosselut; Eric Ballot; Bruno Baudin; Chantal Housset; Sandrine Dabernat; Marie-Lise Lacombe; Mathieu Boissan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-04       Impact factor: 3.000

5.  Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol.

Authors:  Qiang-Ling Sun; Hui-Fang Sha; Xiao-Hua Yang; Guo-Liang Bao; Jing Lu; Yin-Yin Xie
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-25       Impact factor: 4.553

Review 6.  Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.

Authors:  Jian-Ting Zhang; Yang Liu
Journal:  Cancer Treat Rev       Date:  2007-09-12       Impact factor: 12.111

7.  Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.

Authors:  Jin Song; Ie-ming Shih; Daniel W Chan; Zhen Zhang
Journal:  Neoplasia       Date:  2009-06       Impact factor: 5.715

Review 8.  Clinical application of proteomics in ovarian cancer prevention and treatment.

Authors:  Francesco Meani; Sergio Pecorelli; Lance Liotta; Emanuel F Petricoin
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

9.  Proteomic approaches in understanding action mechanisms of metal-based anticancer drugs.

Authors:  Ying Wang; Jen-Fu Chiu
Journal:  Met Based Drugs       Date:  2008

10.  Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.

Authors:  Britta Stordal; Marion Hamon; Victoria McEneaney; Sandra Roche; Jean-Pierre Gillet; John J O'Leary; Michael Gottesman; Martin Clynes
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.